🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

From treatment innovations to real-world data, The UroGist brings together top experts to discuss the latest in #UrologicOncology. Hosted by our EVP Dr. Michael Louie each episode dives into key topics shaping the field.

The current standard of care for patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is an invasive surgical procedure called TURBT. Repeated TURBT and general anesthesia present ongoing treatment challenges for patients.

We are pleased to share results from the Phase 1 dose-escalation study for UGN-301 (zalifrelimab) intravesical solution, an investigational drug in development for the treatment of recurrent non-muscle invasive bladder cancer (NMIBC). #AUA25

During an oral presentation, we presented an updated 18-month duration of response (DOR) from the Phase 3 ENVISION Trial of UGN-102. #AUA25

We are pleased to share new long-term follow-up data from the OPTIMA II Phase 2b study of UGN-102. #AUA25

Today at #AUA25 we presented new patient-reported outcomes from a clinical trial of investigational drug UGN-102.

The current standard of care for treating patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is a transurethral resection of bladder tumor (TURBT). Repeated TURBTs may increase health risks & reduce quality of life.

We’ll be announcing our Q1 2025 financial results during a live audio webcast and conference call on Monday, May 12, 2025, at 10:00 AM ET. Click to learn more. $URGN

#DYK: Low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) impacts tens of thousands annually. With limited treatment options and high recurrence rates, many patients face repeated surgeries to manage the disease. #BladderCancerAwarenessMonth

On May 21, the U.S. FDA Oncologic Drugs Advisory Committee (ODAC) will meet to discuss UGN-102 for treatment of adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

Today, we shared our Q1 2025 financial results. Tune in today at 10:00 AM ET to hear our live, recorded webcast. $URGN

Bladder cancer is highly treatable when detected early. Knowing the symptoms and acting quickly can make all the difference. If you experience any of these signs, talk to your doctor. #BladderCancerAwarenessMonth

Patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) often face recurrence. The current standard of care, transurethral resection of bladder tumor (TURBT), is a surgery requiring anesthesia. #BladderCancerAwarenessMonth

Bladder cancer is the sixth most common cancer in the US. As we wrap up #BladderCancerAwarenessMonth, visit BladderCancerAnswers.com—a resource to help patients better understand non-muscle invasive bladder cancer (NMIBC), its risk factors, and current treatment options.

Members of our team will be participating in a fireside chat at the TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA on May 28, 2025, at 9:00 AM ET. $URGN

Often, patients with low-grade, intermediate-risk non–muscle invasive bladder cancer (LG-IR-NMIBC) face a cycle recurring disease and surgeries. At UroGen, we’re committed to addressing unmet needs because patients deserve more options.

Today at #ASCO25, we announced results from the ENVISION and ATLAS clinical studies exploring investigational therapy UGN-102 (mitomycin) for intravesical solution for the treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

We are pleased to highlight the presentation of the uTRACT Registry study design at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. #ASCO25

Bladder cancer is the 6th most common cancer in the U.S., and for those with LG-IR-NMIBC, recurrence is all too common. Lacey’s story underscores the urgent need for more treatment options. #BladderCancerAwareness

#BREAKING: The U.S. FDA has approved our medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).